Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Zhaohui Zhu, MD
- Phone Number: 86-13611093752
- Email: 13611093752@163.com
Study Contact Backup
- Name: Jiarou Wang, MS
- Phone Number: 86-13628477019
- Email: pumc_wangjiarou@student.pumc.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Zhaohui Zhu, MD
- Phone Number: 86-13611093752
- Email: 13611093752@163.com
-
Contact:
- Jiarou Wang, MS
- Phone Number: 86-13628477019
- Email: pumc_wangjiarou@student.pumc.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- suspected or confirmed pulmonary fibrosis patients;
- signed written consent.
Exclusion Criteria:
- pregnancy;
- breastfeeding;
- known allergy against FAPI
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT
All patients diagnosed with Lung fibrosis underwent 68Ga-FAPI PET/CT and 18F-FDG PET/CT.
|
Intravenous injection of one dosage of 18.5-22.2MBq
(0.5-0.6 mCi)/Kg 68Ga-FAPI.
Tracer doses of 68Ga-FAPI will be used to image lesions of pulmonary fibrosis by PET/CT.
Other Names:
Intravenous injection of one dosage of 4.44-5.55
MBq(0.12-0.15mCi)/Kg
18F-FDG.
Tracer doses of 18F-FDG will be used to image lesions of pulmonary fibrosis by PET/CT.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic value
Time Frame: through study completion, an average of 1 year
|
Sensitivity and Specificity of 68Ga-FAPI PET/CT for Lung fibrosis in comparison with 18F-FDG PET/CT
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
FAPI expression and SUV
Time Frame: through study completion, an average of 1 year
|
Correlation between FAPI expression and SUV in PET
|
through study completion, an average of 1 year
|
|
therapy response
Time Frame: through study completion, an average of 1 year
|
Change of 68Ga-FAPI PET/CT SUVmax after therapy
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Zhaohui Zhu, MD, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PUMCH-NM-FAPI-PF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.